N/A
Manufactured by Vifor (International) Inc.
19,964 FDA adverse event reports analyzed
Last updated: 2026-04-14
METHOXY POLYETHYLENE GLYCOL EPOETIN BETA is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Vifor (International) Inc.. The most commonly reported adverse reactions for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA include DRUG HYPERSENSITIVITY, DEATH, DYSPNOEA, NAUSEA, PRURITUS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA.
Out of 10,838 classified reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 19,964 FDA FAERS reports that mention METHOXY POLYETHYLENE GLYCOL EPOETIN BETA. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG HYPERSENSITIVITY, DEATH, DYSPNOEA, NAUSEA, PRURITUS, VOMITING. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Vifor (International) Inc. in connection with METHOXY POLYETHYLENE GLYCOL EPOETIN BETA. Always verify the specific product and NDC with your pharmacist.